Cell3™ Target: Carrier Screening Panel
Carrier Screening for paediatric recessive disorders
Accurately analyse carrier status of 448 inherited childhood disorders using a single workflow.
Comprehensive content
Designed to enrich for genes with high clinical significance in a broad range of rare, highly penetrant recessive childhood disorders
Streamlined workflow
Consolidate multiple technology workflows into one simple NGS assay. No arrays. No MLPA.
Save time and resources
One workflow saves you time and sample, without compromising on quality or robustness.
Cost effective
Optimised so that as little 2.7Gb of data per sample is required to achieve accurate carrier status.
Expanded carrier screening
Traditionally, molecular research laboratories have based their analysis of carrier status on just a few genetic changes based on family history and/or ethnicity. However, with the advances in next generation sequencing (NGS) and identification of more causative variants—both sequence and structural— it is becoming not just possible but important to expand carrier screening to include more variants and diseases.
That’s why Nonacus have developed Cell3™ Target library preparation solutions for Next Generation Sequencing (NGS). Combining the analysis of SNV’s, indels and CNV’s into a single assay, they enable you to save time and resources and still deliver a comprehensive report on a broad range of penetrant recessive childhood disorders, all from one workflow.
| Type of Disorder | Number of Genes Covered |
|---|---|
| Cardiac | 8 |
| Cutaneous | 45 |
| Deafness | 2 |
| Developmental | 46 |
| Endocrine | 15 |
| Gastroenterologic | 3 |
| Hematologic | 19 |
| Hepatic | 3 |
| Immunodeficiency | 29 |
| Metabolic | 142 |
| Neurodegenerative | 1 |
| Neurological | 119 |
| Neuromuscular | 2 |
| Ocular | 12 |
| Renal | 25 |
| Respiratory | 8 |
| Skeletal | 28 |
| Grand Total | 507 |
Table 1. Range of disorders covered by the Carrier Screening Panel.
Comprehensive coverage of clinically relevant genes
We know that coverage of the most clinically relevant genes is important to you. The 448 disorders represented on the Nonacus Cell3™ Target: Carrier Screening panel all meet the American College of Medical Genetics (ACMG) guidelines and have been selected based on their high penetrance and clinical significance1.
For each gene selected, all coding exons and splice site junctions and intronic, regulatory and untranslated regions known to contain disease mutations have been targeted.
Indepth carrier status report from one test
For expanded carrier screening to be effective we know you need to be able to assess a range of genetic variants including copy number deletions or duplications. We also know that this can mean running a host of workflows from PCR and multiplex ligation-dependent probe amplification (MLPA) to sequencing and microarrays. This not only increases the time it can take you to reach a final report but can have a significant impact on your cost per test.
The Cell3™ Target: Carrier Screening panel streamlines this allowing you to carry out targeted sequencing and copy number analysis and deliver a comprehensive carrier status report from a single test.
| Sequencer | Flow Cell | Samples/Flow Cell | Average Depth (expected) |
|---|---|---|---|
| NextSeq | 300 cycle mid output | 48 | 160x |
| NextSeq | 300 cycle high output | 144 | 160x |
| NovaSeq SP | 300 cycle | 288 | 160x |
| NovaSeq S1 | 200 cycle | n/a | 160x |
| NovaSeq S2 | 200 cycle | n/a | 160x |
| NovaSeq S4 | 200 cycle | n/a | 160x |
Table 2. No. of samples per flow cell to achieve 100x mean depth of coverage based on 2 x 100bp library and maximum quoted sequencer output for Nonacus Carrier Screening Panel.
Maximise sequencing efficiency
By increasing the yield per sample, Nonacus Cell3™ Target library prep solutions allow you to run more samples per flow cell increasing your efficiency and reducing your cost per sample.
Ordering Information
Cell3 Target panels are available with one of two versions of our library preparation kits:
-Fragmentation: for use with gDNA (FF or FFPE)
-Non-Fragmentation: for use with cell free DNA
| Cell3™ Target: Carrier Screening Panel, Frag 16 samples | NGS_C3T_CSP_FR_16 |
| Cell3™ Target: Carrier Screening Panel, Frag 96 samples | NGS_C3T_CSP_FR_96_A/B/C/D* |
| Cell3™ Target: Carrier Screening Panel, Non Frag 16 samples | NGS_C3T_CSP_NF_16 |
| Cell3™ Target: Carrier Screening Panel, Non Frag 96 samples | NGS_C3T_CSP_NF_96_A/B/C/D* |
* To provide flexibility in multiplexing samples, our 96-sample kits offer a choice in adapter plate:
A = Adapter plate with indexes 1-96
B = Adapter plate with indexes 97-192
C = Adapter plate with indexes 193-288
D = Adapter plate with indexes 289-384
Product Resources
Detailed product information available to download.
References
- Bell CJ, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing, Sci Transl Med 2011; 3: 65ra64
For Research Use Only. Not for use in diagnostic procedures.
Product Support
If you have any questions about any of our products, including access to the BED files and example data sets, please fill in the support request form here and we will get back to you as soon as possible.
We offer several NGS cancer panels including the Hereditary Cancer Panel, Bladder Cancer Panel, Pan-Cancer TMB/MSI (524) Panel, Tumor Exome, Actionable Mutation Panel (EGFR), Whole Exome, and Custom NGS panels.